Stronger semaglutide dose, only a modest extra gain

Weight-management drugs have moved quickly from a single option to a crowded field, and prescribing decisions now hinge on how they compare with one another rather than with placebo. Head-to-head trials remain scarce, so clinicians and patients are often choosing between agents on indirect evidence. The recent arrival of a higher 7.2 mg maintenance dose of semaglutide sharpens the question of whether pushing the dose upwards buys meaningfully more weight loss, or mostly more side effects. This review set out to rank the available options on both efficacy and safety over at least a year.

The authors ran a systematic review and frequentist network meta-analysis of phase 3 randomised controlled trials in adults aged 18 or over with a body mass index of 25 kg/m2 or above. Trials had to last at least 52 weeks and compare liraglutide, semaglutide or tirzepatide at approved weight-management doses against placebo or each other. Twenty-four RCTs were included, 23 of them eligible for the network. Random-effects models estimated relative effects and treatments were ranked using P-scores, with outcomes covering body weight, waist circumference, BMI, serious adverse events, any adverse events, injection site reactions and discontinuation due to adverse events.

Every active treatment reduced body weight, waist circumference and BMI compared with placebo. Tirzepatide 15 mg ranked highest for weight and waist reduction across analyses, while liraglutide 3.0 mg yielded the smallest weight loss. Semaglutide 7.2 mg ranked above 2.4 mg for all efficacy endpoints, but a significant advantage in percentage bodyweight change appeared only in the diabetes subgroup, and the authors put the average incremental benefit at roughly 2-3 percentage points. On safety, no significant between-treatment differences emerged for serious adverse events; tirzepatide was associated with more injection site reactions, and liraglutide with higher risks of any adverse event and of discontinuation because of them.

The finding that these agents produce clinically meaningful weight loss over a year or more is now well established, and this analysis confirms it while adding a comparative ordering. What it complicates is the assumption that a higher maintenance dose delivers a proportionally bigger result: the ranking favours 7.2 mg, but the statistical evidence separating it from 2.4 mg is thin outside the diabetes subgroup. Considerable heterogeneity across efficacy outcomes, and reliance on indirect comparisons, mean the rankings should not be read as precise league tables. The authors call for further head-to-head trials and real-world studies to settle dose selection and long-term safety.

This is a reason to think the choice between these drugs involves trade-offs rather than a single best answer, with tolerability sitting alongside weight loss in the calculation. A higher-ranked dose is not the same as a clearly better one when the difference between doses rarely reaches statistical significance. Anyone weighing these medicines is doing so in a clinical conversation, and this synthesis is context for that discussion rather than a substitute for it. It also underlines that the evidence base still lacks the direct comparisons that would settle the ranking properly.